Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 29;366(6469):1139-1143.
doi: 10.1126/science.aaw2900.

Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design

Pierce J Ogden #  1   2   3 , Eric D Kelsic #  4   2   5 , Sam Sinai  1   2   5   6 , George M Church  4   2   3   5
Affiliations

Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design

Pierce J Ogden et al. Science. .

Abstract

Adeno-associated virus (AAV) capsids can deliver transformative gene therapies, but our understanding of AAV biology remains incomplete. We generated the complete first-order AAV2 capsid fitness landscape, characterizing all single-codon substitutions, insertions, and deletions across multiple functions relevant for in vivo delivery. We discovered a frameshifted gene in the VP1 region that expresses a membrane-associated accessory protein that limits AAV production through competitive exclusion. Mutant biodistribution revealed the importance of both surface-exposed and buried residues, with a few phenotypic profiles characterizing most variants. Finally, we algorithmically designed and experimentally verified a diverse in vivo targeted capsid library with viability far exceeding random mutagenesis approaches. These results demonstrate the power of systematic mutagenesis for deciphering complex genomes and the potential of empirical machine-guided protein engineering.

PubMed Disclaimer

Conflict of interest statement

Competing interests: P.J.O., E.D.K., S.S., and G.M.C. are inventors on patent applications filed by Harvard University related to this work. E.D.K., S.S., and G.M.C. hold equity in Dyno Therapeutics, Inc. G.M.C.’s tech transfer and advisory roles are listed at: http://arep.med.harvard.edu/gmc/tech.html.

Figures

Fig. 1.
Fig. 1.. Measurement of all single AAV2 capsid mutations in a multiplexed viral production assay.
(A) Assay and calculation of production fitness (s′). (B) Barcode frequencies: plasmid (fp) versus virus (fv). (C) Fitness for WT replicates and stop codons in VP1, VP2, and VP3. (D) Fitness for all single–amino-acid insertions, deletions (D), stop codons (*), and substitutions. Radius is from capsid center. VR, variable regions. (E) Average fitness for insertions at each position colored on the 3D structure. The triangle is the 3-fold axis and the pentagon is the 5-fold axis. (F) Fitness distributions split by conservation and location within or outside of variable regions. In all panels, *p < 10−20 (Mann–Whitney U test).
Fig. 2.
Fig. 2.. A frameshifted protein expressed from the VP1 region functions through competitive exclusion.
(A) Discovery of MAAP, a frameshifted ORF in theVP1 region. Top: Production fitness for mutations with stop codons in the +1 frame (red) and for cap codons synonymous to the red points but without creating stops in the +1 frame (gray). Solid lines indicatethe 10-position moving average. Bottom: p-value for the observed difference in +1 frame stops and non-stops for the moving window of 10 positions. (B) Westernblot of MAAP-3xFLAG with M2 anti-FLAG HRP antibody and an anti-GAPDH loading control. (C) Membrane association: confocal imaging of MAAP-GFP localization for AAV serotypes 2, 5, 8, and 9. Blue is membrane stain and green is green fluorescent protein. (D) Deleterious effects on production for MAAPstop codons relative to other synonymous codonsin the cap gene, supplying in trans: pRep, pRep+MAAP, or pRep+MAAP negative controls. *p < 10−5 (Mann–Whitney U test). (E) MAAP mutants produce at levels similar to WT when expressed individually (top) are outcompeted by WT in a head-to-head format, but then rescued by pRep+MAAP in trans (bottom). **p < 0.05, ***p < 0.01 (one-way t-test).
Fig. 3.
Fig. 3.. Multiplexed measurement of in vivo biodistribution reveals phenotypic clustering and structural design principles.
(A) Biodistri-bution assay. (B) In vivo selection values for validation mutantsin library format versus individual assays. (C) Projection of individual mutants onto PC1 and PC2 derived from PCA, colored by tissue enrichment. (D) Top: Highlighting k-means clusters of mutants with enhanced tissue targeting. Bottom: Mutant biodistribution values within each cluster. (E) Position of cluster mutants in capsid structure, rendering first all residues and then only residues from each cluster to show the importance of buried residues for cluster 3.
Fig. 4.
Fig. 4.. Machine-guided design of AAV capsids outperforms random mutagenesis.
(A) Left: Generation of multimutants from individual amino-acid liver-biodistribution measurements (black dots: WT). Mutation probability distributions for each position are calculated from single–amino-acid mutant fitness (top). Right: Sampled mutations are combined to generate a multimutant target variant and then all mutants from WT to target are synthesized and experimentally measured (top shows ordering by increasing fitness). (B) Top: Fraction of designed mutants with liver biodistribution values greater than WT for random (gray) and machine-guided design mutants (orange). Bottom: Distribution of biodistribution values for random and designed mutants separated by number of mutations. Even at distances farther than four mutations, the designed approach outperforms random mutagenesis (pink box).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Atchison RW, Casto BC, Hammon WM, Science 149, 754–755 (1965). - PubMed
    1. Russell S et al., Lancet 390, 849–860 (2017). - PMC - PubMed
    1. Mendell JR et al., N. Engl. J. Med 377, 1713–1722 (2017). - PubMed
    1. Wang D, Tai PWL, Gao G, Nat. Rev. Drug Discov 18, 358–378 (2019). - PMC - PubMed
    1. Grimm D, Zolotukhin S, Mol. Ther 23, 1819–1831 (2015). - PMC - PubMed

Publication types

Substances